FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 182 filers reported holding FATE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $115,240 | +38.8% | 35,134 | +210.6% | 0.00% | – |
| Q1 2024 | $83,015 | -57.7% | 11,310 | -78.4% | 0.00% | – |
| Q4 2023 | $196,133 | -76.2% | 52,442 | -86.5% | 0.00% | -100.0% |
| Q3 2023 | $823,103 | -3.2% | 388,256 | +117.3% | 0.00% | -33.3% |
| Q2 2023 | $850,360 | +789.4% | 178,647 | +965.0% | 0.00% | – |
| Q1 2023 | $95,612 | -98.1% | 16,774 | -96.6% | 0.00% | -100.0% |
| Q4 2022 | $4,964,098 | +860.2% | 491,982 | +2030.7% | 0.03% | +800.0% |
| Q3 2022 | $517,000 | -32.7% | 23,090 | +78.2% | 0.00% | -70.0% |
| Q3 2021 | $768,000 | -60.7% | 12,958 | -42.5% | 0.01% | -54.5% |
| Q2 2021 | $1,956,000 | +153.7% | 22,536 | +140.9% | 0.02% | +83.3% |
| Q1 2021 | $771,000 | +188.8% | 9,354 | -31.5% | 0.01% | +50.0% |
| Q4 2019 | $267,000 | – | 13,648 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $11,083,330 | 2.77% |
| Redmile Group, LLC | 13,169,057 | $43,194,507 | 2.61% |
| SUPERSTRING CAPITAL MANAGEMENT LP | 497,360 | $1,631,341 | 2.06% |
| Boxer Capital, LLC | 8,215,910 | $26,948,185 | 1.42% |
| Deep Track Capital, LP | 5,572,607 | $18,278,151 | 0.55% |
| Vestal Point Capital, LP | 2,000,000 | $6,560,000 | 0.49% |
| Bruce & Co., Inc. | 300,000 | $984,000 | 0.32% |
| Octagon Capital Advisors LP | 520,800 | $1,708,224 | 0.27% |
| Integral Health Asset Management, LLC | 850,000 | $2,788,000 | 0.26% |
| Bellevue Group AG | 4,839,779 | $15,874,475 | 0.26% |